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BACKGROUND
In double-blind, placebo-controlled trials, budesonide–formoterol used on an as-
needed basis resulted in a lower risk of severe exacerbation of asthma than as-needed 
use of a short-acting β2-agonist (SABA); the risk was similar to that of budesonide 
maintenance therapy plus as-needed SABA. The availability of data from clinical 
trials designed to better reflect clinical practice would be beneficial.
METHODS
We conducted a 52-week, randomized, open-label, parallel-group, controlled trial 
involving adults with mild asthma. Patients were randomly assigned to one of three 
treatment groups: albuterol (100 μg, two inhalations from a pressurized metered-
dose inhaler as needed for asthma symptoms) (albuterol group); budesonide (200 μg, 
one inhalation through a Turbuhaler twice daily) plus as-needed albuterol (budesonide 
maintenance group); or budesonide–formoterol (200 μg of budesonide and 6 μg of 
formoterol, one inhalation through a Turbuhaler as needed) (budesonide–formoterol 
group). Electronic monitoring of inhalers was used to measure medication use. The 
primary outcome was the annualized rate of asthma exacerbations.
RESULTS
The analysis included 668 of 675 patients who underwent randomization. The an-
nualized exacerbation rate in the budesonide–formoterol group was lower than that 
in the albuterol group (absolute rate, 0.195 vs. 0.400; relative rate, 0.49; 95% con-
fidence interval [CI], 0.33 to 0.72; P<0.001) and did not differ significantly from 
the rate in the budesonide maintenance group (absolute rate, 0.195 in the budesonide–
formoterol group vs. 0.175 in the budesonide maintenance group; relative rate, 1.12; 
95% CI, 0.70 to 1.79; P = 0.65). The number of severe exacerbations was lower in the 
budesonide–formoterol group than in both the albuterol group (9 vs. 23; relative 
risk, 0.40; 95% CI, 0.18 to 0.86) and the budesonide maintenance group (9 vs. 21; 
relative risk, 0.44; 95% CI, 0.20 to 0.96). The mean (±SD) dose of inhaled budesonide 
was 107±109 μg per day in the budesonide–formoterol group and 222±113 μg per 
day in the budesonide maintenance group. The incidence and type of adverse events 
reported were consistent with those in previous trials and with reports in clinical use.
CONCLUSIONS
In an open-label trial involving adults with mild asthma, budesonide–formoterol used 
as needed was superior to albuterol used as needed for the prevention of asthma 
exacerbations. (Funded by AstraZeneca and the Health Research Council of New 
Zealand; Novel START Australian New Zealand Clinical Trials Registry number, 
ACTRN12615000999538.)
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Mild asthma imposes a substantial burden with respect to risk of exacer-bations.1 The risk is reduced by the use 
of inhaled glucocorticoid therapy,2 but this treat-
ment is often not used as recommended because 
of both the reluctance of health care profession-
als to prescribe inhaled glucocorticoid mainte-
nance treatment and the reluctance of patients to 
take it when their symptoms are mild and infre-
quent.3 An alternative strategy is the use of an 
inhaler containing a combination of an inhaled 
glucocorticoid and a fast-onset β2-agonist on an 
as-needed basis as reliever therapy; this strategy 
takes advantage of patients’ natural behavior to 
take reliever therapy when symptomatic4-6 and 
allows them to manage their own use of inhaled 
glucocorticoid therapy according to variations in 
asthma symptoms.
Recently, two randomized, double-blind, pla-
cebo-controlled trials showed the efficacy and 
safety of budesonide–formoterol as reliever therapy 
in the absence of regular maintenance treatment 
in patients with mild asthma.7,8 However, although 
these trials have high internal validity, they have 
limited external validity; whether the findings 
translate to clinical practice outside the setting 
of a rigidly controlled trial is unclear. Both trials 
required participants to use an inhaler twice a 
day for 12 months so that double-blinding could 
be maintained, but this requirement removed the 
advantage of a single inhaler for symptom relief. 
In addition, both trials required that low-dose in-
haled glucocorticoid therapy or leukotriene-recep-
tor antagonist therapy (taken by slightly more than 
half the participants) be withdrawn during a run-
in phase to allow for asthma control to worsen, a 
requirement that is not consistent with clinical 
practice. Furthermore, as a result of a baseline eli-
gibility requirement that a short-acting β2-agonist 
(SABA) be taken more than twice in a week, both 
trials excluded patients with intermittent symp-
toms for whom regular inhaled glucocorticoid 
therapy is currently recommended.9,10
To overcome these limitations, we conducted 
an open-label clinical trial (Novel Symbicort Tur-
buhaler Asthma Reliever Therapy [Novel START]) 
to investigate budesonide–formoterol reliever ther-
apy used on an as-needed basis among adults with 
mild asthma who had been treated with only 
as-needed SABA. We hypothesized that as-need-
ed budesonide–formoterol would be superior to 
as-needed SABA (i.e., continuation of the patients’ 
current class of treatment) and to inhaled gluco-
corticoid maintenance therapy plus as-needed 
SABA (as recommended in current guidelines) in 
preventing asthma exacerbations.9,10
Me thods
Trial Design and Oversight
This 52-week, randomized, open-label, parallel-
group, controlled trial was conducted at 16 trial 
centers that were based in primary and secondary 
care in New Zealand, the United Kingdom, Italy, 
and Australia; a list of the participating centers 
is provided in the Supplementary Appendix, avail-
able with the full text of this article at NEJM.org. 
The trial was designed by the trial investigators 
before consultation with AstraZeneca, who fund-
ed the trial. A summary of the trial design has 
been published previously,11 and the full trial pro-
tocol and statistical analysis plan are available at 
NEJM.org. The protocol was approved by all the 
relevant state and national ethics committees. 
Written informed consent was obtained from all 
the patients before the performance of any trial 
procedures. The global sponsor of the trial, the 
Medical Research Institute of New Zealand (Wel-
lington, New Zealand), had overall responsibility 
for the conduct of the trial and for data manage-
ment. An independent data and safety monitor-
ing committee performed regular safety surveil-
lance. The authors had full access to the trial data 
and vouch for the accuracy and completeness of 
the data and for the fidelity of the trial to the 
protocol. The first author wrote the first draft of 
the manuscript, and all the authors reviewed and 
edited subsequent drafts and agreed with the 
decision to submit the manuscript for publica-
tion. AstraZeneca was provided with a draft copy 
of the manuscript but had no involvement in the 
collection or analysis of the data, in the prepara-
tion of the manuscript, or in the decision to sub-
mit the manuscript for publication.
Patients
Patients were eligible for enrollment in the trial 
if they were 18 to 75 years of age and if they re-
ported that they had received a diagnosis of asth-
ma from a doctor. The main inclusion criteria 
were the use of a SABA as the sole asthma thera-
py in the previous 3 months and patient report of 
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the use of the SABA on at least two occasions, but 
on an average of two or fewer occasions per day, 
in the previous 4 weeks. There was no minimum 
requirement for SABA use among patients who 
had had a severe exacerbation in the previous 12 
months. Key exclusion criteria were hospitaliza-
tion for asthma in the previous 12 months and 
either a patient-reported smoking history of more 
than 20 pack-years or the onset of respiratory 
symptoms after the age of 40 years in current or 
previous smokers with a smoking history of at 
least 10 pack-years (further details are provided 
in the Supplementary Appendix).
Randomization and Treatment
After enrollment, patients were randomly as-
signed, in a 1:1:1 ratio, to one of three treatment 
groups: albuterol used as needed for asthma 
symptoms (albuterol group), budesonide plus 
as-needed albuterol (budesonide maintenance 
group), or budesonide–formoterol used as need-
ed (budesonide–formoterol group). Random-
ization was stratified according to country and 
was performed with the use of a computer-
generated sequence with a block size of nine. An 
electronic clinical record system concealed the 
patients’ treatment assignments until the time of 
randomization. Patients, investigators, and the 
statistician were all aware of the treatment-group 
assignments.
Patients in the albuterol group received alb-
uterol (Ventolin, GlaxoSmithKline), 100 μg, with 
two inhalations from a pressurized metered-dose 
inhaler as needed for symptom relief. Patients in 
the budesonide maintenance group received 
budesonide (Pulmicort Turbuhaler, AstraZeneca), 
200 μg, one inhalation twice daily, plus albuterol 
(Ventolin), 100 μg, two inhalations from a pres-
surized metered-dose inhaler as needed for symp-
tom relief. Patients in the budesonide–formoterol 
group received budesonide–formoterol (Symbicort 
Turbuhaler, AstraZeneca), 200 μg of budesonide 
and 6 μg of formoterol, one inhalation as needed 
for symptom relief. Patients were provided with 
asthma action plans that included instructions 
that specified the circumstances under which 
they should seek medical evaluation for worsen-
ing asthma as well as a log for recording urgent 
medical visits and use of systemic glucocorti-
coids (Figs. S18 through S29 in the Supplemen-
tary Appendix). Electronic inhaler usage monitors 
(Adherium), which record the date and time of 
inhaler actuations,12,13 were incorporated in all 
inhalers dispensed in the trial.
Procedures
Seven trial visits occurred over the course of 52 
weeks: at weeks 0 (randomization), 6, 12, 22, 32, 
42, and 52. Patients were withdrawn because of 
treatment failure if they had one severe exacer-
bation, three exacerbations separated by at least 
7 days, unstable asthma that resulted in a change 
in the treatment assigned to them, or any combi-
nation of these. If none of these events occurred, 
patients remained under the care of their primary 
care physician for management of their asthma 
throughout the period of the trial.
Primary Outcome Measure
The primary outcome was the annualized rate of 
asthma exacerbations per patient. An exacerbation 
was defined as worsening asthma that resulted 
in one or more of the following: an urgent medi-
cal care consultation (e.g., a primary care visit, 
an emergency department [ED] visit, or hospital 
admission); a prescription of systemic glucocor-
ticoids for any duration; or an episode of high 
β2-agonist use, which was defined as more than 
16 actuations of albuterol or more than 8 actua-
tions of budesonide–formoterol over the course 
of 24 hours.14
Secondary Outcome Measures
Key secondary outcome measures included the 
number of exacerbations, defined according to 
each of the three criteria described above, and the 
time to the first exacerbation; the number of se-
vere exacerbations, according to American Tho-
racic Society and European Respiratory Society 
criteria,15 with a severe exacerbation defined as 
worsening asthma leading to the prescription 
of systemic glucocorticoid treatment for at least 
3 days or hospitalization or an ED visit leading to 
systemic glucocorticoid treatment (the number of 
severe exacerbations represents the number of pa-
tients who had a severe exacerbation, since pa-
tients were withdrawn from the trial after they 
had one severe exacerbation); the number of pa-
tients who were withdrawn as a result of treat-
ment failure; the score on the Asthma Control 
Questionnaire–5 (ACQ-5; the mean score of five 
questions that assess asthma symptoms during 
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the previous week, each of which is scored on a 
7-point scale that ranges from 0 [no impairment] 
to 6 [maximum impairment], in which a 0.5-unit 
change represents the minimal clinically impor-
tant difference)16; the on-treatment forced expi-
ratory volume in 1 second (FEV1, in liters)
15; the 
fraction of exhaled nitric oxide (Feno, in parts per 
billion); the electronically recorded daily dose of 
budesonide; oral prednisone use (in milligrams); 
the electronically recorded number of β2-agonist 
actuations per day; and adverse events.
Statistical Analysis
The statistical analysis was an intention-to-treat 
superiority analysis. The prespecified treatment 
comparisons were between as-needed budesonide–
formoterol and as-needed albuterol and between 
as-needed budesonide–formoterol and mainte-
nance budesonide plus as-needed albuterol.
The primary analysis was a comparison of the 
rate of exacerbations per patient per year with the 
use of a Poisson regression model, with days of 
observation as an offset variable. Two sensitivity 
analyses were performed to account for potential 
predictors of response. The first analysis mod-
eled a fixed effect for baseline SABA use and the 
number of severe exacerbations in the previous 
12 months. The second analysis included the same 
two covariates plus age, sex, smoking status, base-
line score on the ACQ-5, Feno, blood eosinophil 
count, and serum periostin level. A time-to-event 
analysis with Kaplan–Meier plots and a Cox pro-
portional-hazards model were used to estimate the 
hazard ratio for a first exacerbation. Interaction 
models were used to test for subgroup effects.
Continuous variables were compared with the 
use of Student’s t-test and linear mixed-effects 
models to account for repeated measurements and 
to examine change over time. For the analysis of 
Feno, the data were log-transformed, and differ-
ences in the logarithms were analyzed as the ratio 
of geometric means.
We estimated that with a sample of 225 pa-
tients in each treatment group, the trial would 
have 80% power to detect a difference of 0.3 ex-
acerbations per patient per year (1.2 vs. 0.9) be-
tween the budesonide–formoterol group and the 
albuterol group and between the budesonide–
formoterol group and the budesonide mainte-
nance group, which represents a relative risk of 
exacerbation of 0.75, at a two-sided alpha level 
of 0.05. This estimated sample size accounted for 
an anticipated dropout rate of 20%.11 All analyses 
were performed with the use of SAS software, ver-
sion 9.4 (SAS Institute).
R esult s
Patients
From March 2016 through August 2017, a total 
of 675 participants underwent randomization; 
the last participant visit occurred in August 2018. 
The baseline characteristics of the 668 patients 
who were included in the analyses are shown in 
Table 1. No follow-up data were available for 13 
patients. No participants were withdrawn by the 
sponsor. Patients had mild asthma, with a mean 
score on the ACQ-5 of 1.1; 7.3% of the patients 
reported a severe exacerbation in the previous 
12 months, and 54% reported using SABA on 
two or fewer occasions per week in the previous 
4 weeks. Additional details about the patients 
are provided in Figure S1 and Tables S2 and S3 
in the Supplementary Appendix.
Primary Outcome
The asthma exacerbation rate in the budesonide–
formoterol group was lower than that in the al-
buterol group (absolute rate per patient per year, 
0.195 vs. 0.400; relative rate, 0.49; 95% confidence 
interval [CI], 0.33 to 0.72; P<0.001) and did not 
differ significantly from that in the budesonide 
maintenance group (absolute rate per patient per 
year, 0.195 in the budesonide–formoterol group 
vs. 0.175 in the budesonide maintenance group; 
relative rate, 1.12; 95% CI, 0.70 to 1.79; P = 0.65) 
(Fig. 1A and 1B, and Tables S5a and S6 in the 
Supplementary Appendix). These relative rates 
were similar in sensitivity analyses that included 
covariates, that included censored exacerbations 
identified after patients were withdrawn owing 
to discontinuation of treatment, and that used 
single-value imputation models that addressed 
the potential effects of informative censoring of 
data from patients who were withdrawn because 
of unstable asthma that resulted in a change in 
the randomly assigned treatment before the end 
of the trial (Tables S7 and S50 through S55 in 
the Supplementary Appendix).
Secondary Exacerbation Outcomes
The risk of exacerbation in the budesonide–for-
moterol group was lower than that in the albuterol 
group, as assessed in a time-to-first-event analysis 
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(hazard ratio, 0.46; 95% CI, 0.29 to 0.73) and did 
not differ significantly from that in the budesonide 
maintenance group (hazard ratio, 0.93; 95% CI, 
0.55 to 1.57) (Fig. 2A, and Table S8 in the Supple-
mentary Appendix). For example, at 300 days of 
follow-up, the Kaplan–Meier estimates of the per-
centage of patients who had had an exacerbation 
were 23.0% in the albuterol group, 12.5% in the 
budesonide maintenance group, and 11.9% in the 
budesonide–formoterol group.
Characteristic
Albuterol 
Group 
(N = 223)
Budesonide 
Maintenance 
Group 
(N = 225)
Budesonide–
Formoterol 
Group 
(N = 220)
Age — yr 35.8±14.0 34.9±14.3 36±14.1
Female sex — no. (%) 113 (50.7) 129 (57.3) 122 (55.5)
Current smoker — no. (%) 24 (10.8) 22 (9.8) 18 (8.2)
Patient-reported SABA use in the 4 weeks before en-
rollment
No. of occasions per wk
Mean 3.4±3.3 3.2±3.0 3.8±3.5
Median (IQR) 2 (1–4) 2 (1–4) 3 (1–5)
Range 0–14 0.5–14 0.5–14
Patients who had ≤2 occasions per wk — no. (%) 127 (57.0) 132 (58.7) 105 (47.7)
Puffs per wk
Mean 6.52±7.83 5.82±5.25 6.98±6.91
Median (IQR) 4 (2–8) 4 (2–7) 4 (2–8)
Range 0–84 0.5–28 0.5–42
No. of hospital admissions for asthma at any time be-
fore enrollment — mean per patient
0.3±0.9 0.3±0.9 0.3±1.3
No. of severe exacerbations in the previous 12 mo. — 
no. (%)
0 203 (91.0) 208 (92.4) 208 (94.5)
1 20 (9.0) 15 (6.7) 12 (5.5)
2 0 2 (0.9) 0
Any 20 (9.0) 17 (7.6) 12 (5.5)
ACQ-5 score† 1.1±0.7 1.1±0.7 1.1±0.7
On-treatment FEV1 — % of predicted value‡ 89.2±13.7 90.3±13.6 89.8±14.1
Median Feno (range) — ppb 40 (5–235) 38 (5–200) 37 (3–300)
Periostin — ng/ml 69.3±28.9 70.6±27.8 70.8±27.0
Blood eosinophil count — ×10−9 per liter 0.3±0.2 0.3±0.2 0.3±0.2
*  Plus–minus values are means ±SD. Patients in the albuterol group received albuterol (Ventolin, GlaxoSmithKline), 100 μg, 
with two inhalations from a pressurized metered-dose inhaler as needed for symptom relief. Patients in the budesonide 
maintenance group received budesonide (Pulmicort Turbuhaler, AstraZeneca), 200 μg, one inhalation twice daily, plus 
albuterol (Ventolin), 100 μg, two inhalations from a pressurized metered-dose inhaler as needed for symptom relief. 
Patients in the budesonide–formoterol group received budesonide–formoterol (Symbicort Turbuhaler, AstraZeneca), 
200 μg of budesonide and 6 μg of formoterol, one inhalation as needed for symptom relief. Feno denotes fraction of ex-
haled nitric oxide, FEV1 forced expiratory volume in 1 second, IQR interquartile range, ppb parts per billion, and SABA 
short-acting β2-agonist.
†  The Asthma Control Questionnaire–5 (ACQ-5) consists of five questions that assess asthma symptoms in the previous 
week, each of which is scored on a 7-point scale that ranges from 0 (no impairment) to 6 (maximum impairment), in 
which a 0.5-unit change represents the minimal clinically important difference.
‡  Patients receive no specific instruction to withhold use of their bronchodilator before measurement of FEV1.15
Table 1. Characteristics of the Patients at Baseline.*
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Figure 1. Exacerbation Results and Median Feno over Time.
Patients in the albuterol group received albuterol (Ventolin, GlaxoSmithKline), 100 μg, with two inhalations from a pressurized metered-
dose inhaler as needed for symptom relief. Patients in the budesonide maintenance group received budesonide (Pulmicort Turbuhaler, 
AstraZeneca), 200 μg, one inhalation twice daily, plus albuterol (Ventolin), 100 μg, two inhalations from a pressurized metered-dose in-
haler as needed for symptom relief. Patients in the budesonide–formoterol group received budesonide–formoterol (Symbicort Turbuhal-
er, AstraZeneca), 200 μg of budesonide and 6 μg of formoterol, one inhalation as needed for symptom relief. Panel A shows the number 
of times exacerbation criteria were met (with exacerbation defined as worsening asthma that resulted in an episode of high β2-agonist 
inhaler use, in an urgent medical care consultation, or in a course of systemic glucocorticoids). A single exacerbation could have been 
characterized by more than one criterion. For example, a patient could have had an episode of high β2-agonist use, after which the pa-
tient sought urgent medical care and then received a course of systemic glucocorticoids; this scenario would represent a single exacer-
bation, in which the patient met all three criteria. Panel B shows the rate of exacerbations per patient per year, and Panel C the number 
of severe exacerbations. In both panels, I bars indicate 95% confidence intervals. Panel D shows the median fraction of exhaled nitric 
oxide (Feno, in parts per billion [ppb]) at baseline (visit 1), at 12 weeks (visit 3), and at 52 weeks (visit 7); I bars indicate the interquartile 
range (IQR).
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The number of severe exacerbations in the 
budesonide–formoterol group was lower than the 
number in both the albuterol group (9 vs. 23; rela-
tive risk, 0.40; 95% CI, 0.18 to 0.86) and the 
budesonide maintenance group (9 vs. 21; relative 
risk, 0.44; 95% CI, 0.20 to 0.96) (Figs. 1C and 2B, 
and Table S13 in the Supplementary Appendix).
A set of prespecified subgroup analyses, which 
tested the interaction of randomly assigned treat-
ment with various subgroups, identified no con-
sistent evidence of effect modification with respect 
to exacerbations, severe exacerbations, or score 
on the ACQ-5 in subgroups defined according to 
age, sex, baseline smoking status, history of ex-
acerbations, baseline SABA use, baseline score on 
the ACQ-5, predicted FEV1, baseline blood eosino-
phil count, baseline Feno, baseline serum perios-
tin level, and baseline score for type 2 airway in-
flammation (which was based on thirds of each 
baseline measurement of eosinophil count, Feno, 
and periostin level). (Details are provided in 
Tables S56 through S58 and Figures S12 through 
S17 in the Supplementary Appendix.)
The number of patients who were withdrawn 
because of treatment failure in the budesonide–
formoterol group was lower than the number in 
the albuterol group (12 vs. 37; relative risk, 0.33; 
95% CI, 0.17 to 0.63) but did not differ signifi-
cantly from the number in the budesonide main-
tenance group (12 in the budesonide–formoterol 
group vs. 22 in the budesonide maintenance 
group; relative risk, 0.56; 95% CI, 0.28 to 1.13) 
(Table S18 in the Supplementary Appendix).
Other Secondary Outcomes
Across all time points, the score on the ACQ-5 
was lower in the budesonide–formoterol group 
than in the albuterol group (mean difference, 
−0.15; 95% CI, −0.24 to −0.06) but was higher in 
the budesonide–formoterol group than in the 
budesonide maintenance group (mean difference, 
0.14; 95% CI, 0.05 to 0.23) (Table S35 and Fig. S8 
in the Supplementary Appendix).
Across all time points, the FEV1 in the 
budesonide–formoterol group did not differ sig-
nificantly from the FEV1 in either the albuterol 
group (mean difference, 0.03 liters; 95% CI, 
−0.006 to 0.07) or the budesonide maintenance 
group (mean difference, 0.004 liters; 95% CI, −0.03 
to 0.04) (Table S38 and Fig. S9 in the Supple-
mentary Appendix).
The distribution of Feno was widely skewed at 
baseline; the median Feno was 40 parts per bil-
lion (ppb) (range, 5 to 235; interquartile range, 
23 to 75) in the albuterol group, 38 ppb (range, 
5 to 200; interquartile range, 20 to 76) in the 
Figure 2. Kaplan–Meier Estimates of the First Occurrence of Exacerbation 
in a Time-to-Event Analysis.
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budesonide maintenance group, and 37 ppb 
(range, 3 to 300; interquartile range, 18 to 66) in 
the budesonide–formoterol group. At 12 months 
(visit 7), the median Feno values were 36 ppb 
(range, 5 to 201; interquartile range, 22 to 66) in 
the albuterol group, 25 ppb (range, 4 to 186; 
interquartile range, 16 to 45) in the budesonide 
maintenance group, and 26 ppb (range, 5 to 238; 
interquartile range, 16 to 48) in the budesonide–
formoterol group (Fig. 1D, and Fig. S6 and Table 
S25 in the Supplementary Appendix). The geo-
metric mean Feno in the budesonide–formoterol 
group was lower than that in the albuterol group 
(ratio of geometric means, 0.83; 95% CI, 0.75 to 
0.91) but higher than that in the budesonide 
maintenance group (ratio of geometric means, 
1.13; 95% CI, 1.02 to 1.25) at 12 months (Table 
S32 in the Supplementary Appendix).
The mean (±SD) dose of budesonide was 
107±109 μg per day in the budesonide–formoterol 
group and 222±113 μg per day in the budesonide 
maintenance group (Table 2). Overall mean ad-
herence to twice-daily doses of budesonide main-
tenance therapy was 56%.
Adverse events and serious adverse events are 
summarized in Table 3, and in Tables S59 
through S62 in the Supplementary Appendix. 
There was one death (motor vehicle accident) in 
the budesonide–formoterol group and one death 
(suicide) in the budesonide maintenance group 
(Table S62 in the Supplementary Appendix).
Discussion
The results of this randomized, open-label, con-
trolled trial showed that, among patients with 
mild asthma who had previously been taking only 
a SABA on an as-needed basis, the risk of asthma 
exacerbations was lower with budesonide–for-
moterol used as needed than with albuterol used 
as needed. Treatment with as-needed budesonide–
formoterol was superior to both as-needed albu-
terol and budesonide maintenance therapy plus 
as-needed albuterol in reducing the risk of severe 
exacerbations. This finding suggests that the use 
of an inhaled glucocorticoid in the situation of 
worsening asthma as perceived by the patient, 
through the vehicle of a coadministered broncho-
dilator (such as formoterol) used on an as-need-
ed basis, may reduce the risk of the exacerbation 
Outcome
Albuterol  
Group 
(N = 223)
Budesonide 
Maintenance 
Group 
(N = 225)
Budesonide–
Formoterol 
Group 
(N = 220)
Glucocorticoid use
No. of inhaled glucocorticoid-containing actuations 
per day
Mean NA 1.11±0.56 0.53±0.54
Median (IQR) NA 1.23 (0.66–1.57) 0.37 (0.15–0.73)
Range NA 0–2.01 0–3.95
Daily budesonide dose — μg
Mean NA 222±113 107±109
Median (IQR) NA 247 (132–314) 73 (31–146)
Range† NA 0–402 0–790
Oral glucocorticoid use, prednisone — mg 17.4±59.8 14.5±51.0 7.5±40.2
No. of β2-agonist–containing actuations per day
Mean 1.01±1.60 0.52±1.03 0.53±0.54
Median (IQR) 0.50 (0.18–1.18) 0.18 (0.06–0.46) 0.37 (0.15–0.73)
Range 0.0–16.3 0.0–8.7 0–3.95
*  Plus–minus values are means ±SD. Inhaled glucocorticoid and β2-agonist use was determined with the use of electron-
ic monitoring of the trial inhalers. NA denotes not applicable.
†  The range refers to the minimum mean daily dose and the maximum mean daily dose.
Table 2. Medication Outcomes.*
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becoming severe enough for the patient to seek 
urgent care. However, maintenance treatment with 
budesonide was superior for control of asthma 
symptoms, which suggests that for the patient for 
whom asthma symptoms rather than exacerba-
tions are the most bothersome, maintenance treat-
ment has value.
This trial extends the findings of the double-
blind, double-dummy Symbicort Given as Needed 
in Mild Asthma (SYGMA) trials7,8 to an open-label 
treatment regimen that reflects real-world prac-
tice. Our population had less severe asthma than 
the patients in the SYGMA trials, given that the 
patients in our trial were taking only a SABA at 
enrollment and approximately half reported us-
ing a SABA on an average of two or fewer occa-
sions per week at enrollment, which was a key 
exclusion criterion in the final week of run-in in 
the SYGMA trials. As a result, our trial extends 
the evidence for the efficacy of as-needed use of 
budesonide–formoterol to a level at which initia-
tion of inhaled glucocorticoid therapy is recom-
mended by the Global Initiative for Asthma for 
risk reduction9 — although the therapy is often 
not prescribed or taken. The SYGMA 1 trial showed 
that the risk of severe exacerbation was 64% 
lower with as-needed budesonide–formoterol 
than with as-needed SABA,7 which was similar 
to the estimate of 60% in the current trial. How-
ever, whereas the SYGMA 1 and 2 trials showed 
no significant difference in the risk of severe 
exacerbations between as-needed budesonide–
formoterol and budesonide maintenance therapy 
plus as-needed terbutaline (risk ratios of 0.83 
and 0.97, respectively),7,8 we observed fewer severe 
exacerbations with as-needed budesonide–for-
moterol than with budesonide maintenance ther-
apy plus as-needed albuterol (relative risk, 0.44). 
Event
Albuterol 
Group 
(N = 226)
Budesonide 
Maintenance 
Group 
(N = 227)
Budesonide–
Formoterol 
Group 
(N = 222)
number of patients (percent)
Any adverse event 185 (81.9) 190 (83.7) 174 (78.4)
Adverse events that occurred in ≥2% of pa-
tients in any group
Upper respiratory tract infection 75 (33.2) 75 (33.0) 71 (32.0)
Nasopharyngitis 46 (20.4) 35 (15.4) 47 (21.2)
Asthma 46 (20.4) 26 (11.5) 17 (7.7)
Influenza 17 (7.5) 25 (11.0) 20 (9.0)
Lower respiratory tract infection 20 (8.8) 18 (7.9) 14 (6.3)
Headache 15 (6.6) 14 (6.2) 9 (4.1)
Cough 12 (5.3) 14 (6.2) 10 (4.5)
Respiratory tract infection 7 (3.1) 11 (4.8) 10 (4.5)
Seasonal allergy 12 (5.3) 8 (3.5) 7 (3.2)
Sinusitis 7 (3.1) 10 (4.4) 9 (4.1)
Back pain 9 (4.0) 7 (3.1) 7 (3.2)
Oropharyngeal pain 10 (4.4) 7 (3.1) 5 (2.3)
Ligament sprain 7 (3.1) 6 (2.6) 8 (3.6)
Gastroenteritis 8 (3.5) 8 (3.5) 4 (1.8)
Anxiety 7 (3.1) 6 (2.6) 6 (2.7)
Viral upper respiratory tract infection 5 (2.2) 8 (3.5) 6 (2.7)
Toothache 4 (1.8) 9 (4.0) 1 (0.5)
Migraine 7 (3.1) 2 (0.9) 5 (2.3)
Table 3. Adverse Events.
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This difference may relate to our open-label de-
sign, which, through avoidance of a double-dum-
my design, allowed the use of a single inhaler for 
both an inhaled glucocorticoid and a beta ago-
nist and no requirement for regular inhaler use 
twice daily (i.e., the placebo inhalers in the two 
SYGMA trials), which are real-world advantages 
of the regimen of as-needed budesonide–for-
moterol.
An unexpected observation was that budesonide 
maintenance therapy plus as-needed albuterol did 
not appear to result in a lower number of severe 
exacerbations than as-needed albuterol. The most 
likely explanation for this finding is bias due to 
protocol-driven withdrawals. Patients were with-
drawn because of treatment failure if they had 
one severe exacerbation, three exacerbations sep-
arated by at least 7 days, unstable asthma that 
resulted in a change in the assigned treatment, 
or any combination of these. The criterion for a 
change in the assigned treatment by the treating 
physician because of unstable asthma was met 
by 11 patients in the albuterol group; for all 
these patients, an inhaled glucocorticoid or an 
inhaled glucocorticoid–long-acting beta agonist 
(LABA) was subsequently prescribed, whereas 
these medications were not prescribed for un-
stable asthma for any patients in the other two 
groups, because no patients in those groups met 
the criteria for unstable asthma that resulted in 
a change in the assigned treatment. In the alb-
uterol group, withdrawal because of a change in 
the assigned treatment owing to unstable asthma 
may have led to a healthy survivor effect because 
of a reduced pool of patients in unstable condi-
tion who could otherwise have gone on to have 
a severe exacerbation. When withdrawal because 
of treatment failure according to all three crite-
ria was taken into account, the number of with-
drawals was higher in the albuterol group than 
in the budesonide maintenance group (37 vs. 22).
The findings of our trial are consistent with 
evidence regarding the treatment of moderate 
and severe asthma — that maintenance and re-
liever therapy with inhaled glucocorticoid–for-
moterol results in a lower risk of severe exacer-
bations than maintenance therapy with an inhaled 
glucocorticoid–LABA and as-needed SABA14,17; that 
frequent repeated administration of high-dose 
inhaled glucocorticoid in patients with acute se-
vere asthma has similar efficacy to an oral gluco-
corticoid18,19; that in adults, quadrupling the dose 
of inhaled glucocorticoid during worsening asth-
ma results in fewer severe exacerbations20; and 
that combination beclomethasone dipropionate–
albuterol used as needed has greater efficacy than 
as-needed albuterol alone.21
A reduction in the median Feno from baseline 
to month 12 was observed with budesonide main-
tenance therapy (from 38 to 25 ppb) and with 
as-needed budesonide–formoterol (from 37 to 26 
ppb), which indicates that in patients with mild 
asthma who have not been treated previously 
with a glucocorticoid, airway inflammation as 
measured by Feno is highly responsive to inhaled 
glucocorticoid therapy. These findings show that 
budesonide–formoterol therapy has antiinflam-
matory activity in the airway when administered 
according to an as-needed reliever regimen for 
the treatment of mild asthma.
Limitations of the current trial include the 
occurrence of more frequent scheduled clinic 
visits than would be expected in routine clinical 
practice and patient awareness of the electronic 
monitoring of inhaler use. The open-label design 
introduced potential for bias but avoided the re-
quirement for double-dummy medication use. 
The exacerbation rate was lower than anticipated; 
however, the magnitude of the difference be-
tween the budesonide–formoterol group and the 
albuterol group in the relative rate was greater 
than predicted, and there was sufficient power 
to identify a significant difference in these exac-
erbation rates, although confidence intervals were 
wide. Secondary outcomes were not adjusted for 
multiplicity of analyses and should not be used 
to infer definitive treatment effects. Strengths of 
the trial include the use of validated electronic 
inhaler monitors to calculate inhaled glucocorti-
coid exposure and to identify otherwise unre-
ported exacerbations that were not severe.14 The 
analysis of the primary outcome of the asthma 
exacerbation rate was based on a composite in-
dication of worsening asthma that included both 
urgent medical review or prescription of systemic 
glucocorticoids and episodes of high β2-agonist 
use — thereby including exacerbations that did 
not lead the patient to seek urgent care. The 
thresholds for high β2-agonist use were based on 
recommended levels at which a patient should 
seek medical review22 and reflect that repeat ad-
ministration of formoterol at a dose of 6 μg results 
in a short-term bronchodilator response that is 
similar to that observed with repeat administra-
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tion of albuterol at a dose of 200 μg in the treat-
ment of acute asthma.23,24
In conclusion, this clinical trial, in which an 
open-label design was used to reflect clinical prac-
tice, showed that budesonide–formoterol used as 
needed was superior to albuterol used as needed 
for the prevention of exacerbations in adults with 
mild asthma.
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